CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 79% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English

Trade Praxis Precision Medicines, Inc. - PRAX CFD

17.32
2.97%
  • Summary
  • Historical Data
  • Events
  • Income Statement
  • Balance Sheet
  • Cash Flow
  • Ownership
Trading Conditions
Spread 0.27
Long position overnight fee

Long position overnight fee


Margin. Your investment $1,000.00
Overnight fee -0.026235 %
Charges from full value of position ($-4.98)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
-0.026235%
Short position overnight fee

Short position overnight fee


Margin. Your investment $1,000.00
Overnight fee 0.004012 %
Charges from full value of position ($0.76)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
0.004012%
Overnight fee time 22:00 (UTC)
Min traded quantity 1
Currency USD
Margin 5%
Stock exchange United States of America
Commission on trade 0%

*Information provided by Capital.com

Praxis Precision Medicines Inc ESG Risk Ratings

High Medium Low Negligible

‘D’ score indicates poor relative ESG performance and insufficient degree of transparency in reporting material ESG data publicly.

More ESG coverage

Key Stats
Prev. Close* 17.85
Open* 17.47
1-Year Change* 697.72%
Day's Range* 16.67 - 17.47
52 wk Range 0.79-5.25
Average Volume (10 days) 448.19K
Average Volume (3 months) 16.48M
Market Cap 137.55M
P/E Ratio -100.00K
Shares Outstanding 128.55M
Revenue 1.93M
EPS -2.24
Dividend (Yield %) N/A
Beta -100.00K
Next Earnings Date Feb 5, 2024

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Dec 1, 2023 17.32 -0.15 -0.86% 17.47 17.73 16.01
Nov 30, 2023 17.85 0.88 5.19% 16.97 18.28 16.97
Nov 29, 2023 17.19 1.43 9.07% 15.76 17.97 14.74
Nov 28, 2023 1.08 -0.07 -6.09% 1.15 1.16 1.05
Nov 27, 2023 1.19 0.06 5.31% 1.13 1.23 1.13
Nov 24, 2023 1.14 0.05 4.59% 1.09 1.21 1.09
Nov 22, 2023 1.11 0.07 6.73% 1.04 1.14 1.04
Nov 21, 2023 1.05 -0.08 -7.08% 1.13 1.19 1.04
Nov 20, 2023 1.19 0.18 17.82% 1.01 1.23 0.98
Nov 17, 2023 0.98 0.04 4.26% 0.94 1.01 0.93
Nov 16, 2023 0.94 -0.02 -2.08% 0.96 0.99 0.91
Nov 15, 2023 0.95 0.07 7.95% 0.88 0.98 0.88
Nov 14, 2023 0.88 0.03 3.53% 0.85 0.93 0.85
Nov 13, 2023 0.85 -0.11 -11.46% 0.96 0.96 0.85
Nov 10, 2023 0.96 0.01 1.05% 0.95 0.96 0.89
Nov 9, 2023 0.95 -0.02 -2.06% 0.97 1.04 0.92
Nov 8, 2023 0.98 -0.05 -4.85% 1.03 1.03 0.93
Nov 7, 2023 1.01 -0.01 -0.98% 1.02 1.06 0.98
Nov 6, 2023 0.96 -0.09 -8.57% 1.05 1.08 0.96
Nov 3, 2023 1.08 0.13 13.68% 0.95 1.08 0.95

Praxis Precision Medicines, Inc. Events

Time (UTC) Country Event
Monday, February 5, 2024

Time (UTC)

13:30

Country

US

Event

Q4 2023 Praxis Precision Medicines Inc Earnings Release
Q4 2023 Praxis Precision Medicines Inc Earnings Release

Forecast

-

Previous

-
View all events
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total revenue 0 0 0 0 0
Total Operating Expense 214.986 167.332 61.968 35.789 22.719
Selling/General/Admin. Expenses, Total 59.546 47.075 16.992 6.232 3.899
Research & Development 154.44 120.257 44.976 29.557 18.82
Operating Income -214.986 -167.332 -61.968 -35.789 -22.719
Interest Income (Expense), Net Non-Operating 0.957 0.271 0.14 0.193 -0.035
Other, Net 0 -3.648
Net Income Before Taxes -214.029 -167.061 -61.828 -35.596 -26.402
Net Income After Taxes -214.029 -167.061 -61.82 -35.512 -26.535
Net Income Before Extra. Items -214.029 -167.061 -61.82 -35.512 -26.535
Net Income -214.029 -167.061 -61.82 -35.512 -26.535
Total Adjustments to Net Income 0 -8.503 -5.17 -2.688
Income Available to Common Excl. Extra. Items -214.029 -167.061 -70.323 -40.682 -29.223
Income Available to Common Incl. Extra. Items -214.029 -167.061 -70.323 -40.682 -29.223
Diluted Net Income -214.029 -167.061 -70.323 -40.682 -29.223
Diluted Weighted Average Shares 46.0967 42.4541 38.5791 34.1161 34.1161
Diluted EPS Excluding Extraordinary Items -4.64304 -3.9351 -1.82283 -1.19246 -0.85657
Dividends per Share - Common Stock Primary Issue 0 0
Diluted Normalized EPS -4.62135 -3.9351 -1.82283 -1.19246 -0.85657
Unusual Expense (Income) 1
Jun 2023 Mar 2023 Dec 2022 Sep 2022 Jun 2022
Total revenue 0.781 0.683 0 0 0
Total Operating Expense 35.741 38.774 41.453 44.29 60.394
Selling/General/Admin. Expenses, Total 10.127 13.27 13.124 13.851 16.374
Research & Development 25.614 25.504 28.329 30.439 43.02
Operating Income -34.96 -38.091 -41.453 -44.29 -60.394
Interest Income (Expense), Net Non-Operating 0.648 0.636 0.28 0.345 0.2
Net Income Before Taxes -34.312 -37.455 -41.173 -43.945 -60.194
Net Income After Taxes -34.312 -37.455 -41.173 -43.945 -60.194
Net Income Before Extra. Items -34.312 -37.455 -41.173 -43.945 -60.194
Net Income -34.312 -37.455 -41.173 -43.945 -60.194
Total Adjustments to Net Income
Income Available to Common Excl. Extra. Items -34.312 -37.455 -41.173 -43.945 -60.194
Income Available to Common Incl. Extra. Items -34.312 -37.455 -41.173 -43.945 -60.194
Diluted Net Income -34.312 -37.455 -41.173 -43.945 -60.194
Diluted Weighted Average Shares 69.7407 53.1029 47.6113 45.7744 45.5426
Diluted EPS Excluding Extraordinary Items -0.49199 -0.70533 -0.86477 -0.96003 -1.32171
Dividends per Share - Common Stock Primary Issue 0 0 0 0
Diluted Normalized EPS -0.49199 -0.70533 -0.86477 -0.96003 -1.29975
Unusual Expense (Income) 0 1
Revenue 0.781 0.683
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total Current Assets 110.84 287.409 302.326 45.496 19.126
Cash and Short Term Investments 100.489 275.911 296.608 44.815 17.95
Cash & Equivalents 61.615 138.704 296.608 44.815 17.95
Prepaid Expenses 10.351 11.498 5.718 0.681 1.176
Total Assets 115.128 292.747 303.177 47.694 19.829
Property/Plant/Equipment, Total - Net 3.872 4.866 0.836 1.578 0.103
Property/Plant/Equipment, Total - Gross 4.444 5.019 0.924 1.616 0.104
Accumulated Depreciation, Total -0.572 -0.153 -0.088 -0.038 -0.001
Other Long Term Assets, Total 0.416 0.472 0.015 0.62 0.6
Total Current Liabilities 34.345 38.434 15.72 6.818 5.145
Accounts Payable 14.672 10.78 4.088 2.667 3.391
Accrued Expenses 16.855 27.654 11.632 4.151 1.754
Notes Payable/Short Term Debt 0 0 0 0 0
Total Liabilities 39.022 41.935 15.72 7.581 5.147
Total Long Term Debt 0 0 0 0 0
Other Liabilities, Total 4.677 3.501 0 0.763 0.002
Total Equity 76.106 250.812 287.457 40.113 14.682
Redeemable Preferred Stock 0 0 0 121.121 55.72
Common Stock 0.005 0.005 0.004 0.001 0.001
Additional Paid-In Capital 606.918 567.598 437.007 0 0.326
Retained Earnings (Accumulated Deficit) -530.644 -316.615 -149.554 -81.009 -41.365
Total Liabilities & Shareholders’ Equity 115.128 292.747 303.177 47.694 19.829
Total Common Shares Outstanding 49.3825 45.3005 38.2685 34.1161 34.1161
Short Term Investments 38.874 137.207
Other Equity, Total -0.173 -0.176
Other Current Liabilities, Total 2.818
Sep 2023 Jun 2023 Mar 2023 Dec 2022 Sep 2022
Total Current Assets 103.327 129.829 94.402 110.84 132.312
Cash and Short Term Investments 101.085 124.3 85.822 100.489 123.74
Cash & Equivalents 101.085 124.3 80.839 61.615 62.44
Short Term Investments 0 0 4.983 38.874 61.3
Prepaid Expenses 2.242 5.529 8.58 10.351 8.572
Total Assets 106.725 133.498 98.383 115.128 136.902
Property/Plant/Equipment, Total - Net 2.982 3.253 3.565 3.872 4.174
Other Long Term Assets, Total 0.416 0.416 0.416 0.416 0.416
Total Current Liabilities 16.792 24.43 29.916 34.345 28.983
Accounts Payable 7.166 8.01 16.986 14.672 10.122
Accrued Expenses 8.074 14.381 10.387 16.855 18.861
Notes Payable/Short Term Debt 0 0 0 0 0
Total Liabilities 19.969 27.873 33.915 39.022 31.739
Total Long Term Debt 0 0 0 0 0
Total Equity 86.756 105.625 64.468 76.106 105.163
Redeemable Preferred Stock 0 0 0 0
Common Stock 0.013 0.013 0.006 0.005 0.005
Additional Paid-In Capital 713.786 708.023 632.58 606.918 595.165
Retained Earnings (Accumulated Deficit) -627.043 -602.411 -568.099 -530.644 -489.471
Other Equity, Total 0 0 -0.019 -0.173 -0.536
Total Liabilities & Shareholders’ Equity 106.725 133.498 98.383 115.128 136.902
Total Common Shares Outstanding 128.547 128.54 57.9604 49.3825 46.8643
Other Liabilities, Total 3.177 3.443 3.999 4.677 2.756
Other Current Liabilities, Total 1.552 2.039 2.543 2.818
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Net income/Starting Line -214.029 -167.061 -61.82 -35.512 -26.535
Cash From Operating Activities -185.043 -124.554 -52.623 -33.42 -20.721
Cash From Operating Activities 0.419 0.182 0.05 0.037 0.001
Non-Cash Items 35.348 26.192 5.907 1.31 4.354
Changes in Working Capital -6.781 16.133 3.24 0.745 1.459
Cash From Investing Activities 96.889 -140.52 0 -0.103 -0.063
Capital Expenditures -0.444 -1.05 0 -0.103 -0.063
Cash From Financing Activities 10.465 107.586 304.416 60.388 37.804
Issuance (Retirement) of Stock, Net 10.987 108.161 304.416 60.388 36.804
Issuance (Retirement) of Debt, Net 0 1
Net Change in Cash -77.689 -157.488 251.793 26.865 17.02
Other Investing Cash Flow Items, Total 97.333 -139.47
Financing Cash Flow Items -0.522 -0.575
Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
Net income/Starting Line -37.455 -214.029 -172.856 -128.911 -68.717
Cash From Operating Activities -32.846 -185.043 -156.237 -111.318 -54.109
Cash From Operating Activities 0.106 0.419 0.314 0.212 0.093
Non-Cash Items 7.156 35.348 23.59 16.461 8.441
Changes in Working Capital -2.653 -6.781 -7.285 0.92 6.074
Cash From Investing Activities 34 96.889 74.295 26.34 -8.55
Capital Expenditures 0 -0.444 -0.444 -0.399 -0.289
Other Investing Cash Flow Items, Total 34 97.333 74.739 26.739 -8.261
Cash From Financing Activities 18.07 10.465 5.078 1.713 1.209
Financing Cash Flow Items -0.127 -0.522 -0.515 -0.508 -0.492
Issuance (Retirement) of Stock, Net 18.197 10.987 5.593 2.221 1.701
Net Change in Cash 19.224 -77.689 -76.864 -83.265 -61.45
Investor Name Investor Type Percent Outstanding Shares Held Shares change Holdings Date Turnover Rating
Point72 Asset Management, L.P. Hedge Fund 8.2071 10550000 10500000 2023-06-30 HIGH
Verition Fund Management LLC Hedge Fund 8.1587 10487828 7525493 2023-06-30 HIGH
Cormorant Asset Management, LP Hedge Fund 7.3903 9500000 9500000 2023-06-30 LOW
PFM Health Sciences, LP Hedge Fund 6.9171 8891762 6715168 2023-06-30 MED
Sphera Funds Management Ltd. Hedge Fund 6.818 8764334 8764334 2023-06-30 LOW
Adage Capital Management, L.P. Hedge Fund 6.1694 7930638 6008376 2023-06-30 LOW
VR Adviser, LLC Venture Capital 4.1264 5304410 5304410 2023-06-30 MED
Kingdon Capital Management, L.L.C. Hedge Fund 4.0452 5200000 500000 2023-06-30 HIGH
Velan Capital Investment Management LP Investment Advisor/Hedge Fund 4.0335 5185000 0 2023-06-30 HIGH
Tri Locum Partners LP Hedge Fund 3.7999 4884621 1447909 2023-06-30 HIGH
BofA Global Research (US) Research Firm 3.4635 4452174 426405 2023-06-30 LOW
Acuta Capital Partners, LLC Hedge Fund 3.3062 4250000 4250000 2023-06-30 HIGH
SilverArc Capital Management, LLC Hedge Fund 2.7042 3476162 3476162 2023-06-30 HIGH
Ally Bridge Group NY LLC Hedge Fund 2.4894 3200000 3200000 2023-06-30 HIGH
Panacea Venture Venture Capital 2.0615 2650000 2650000 2023-03-10 LOW
The Vanguard Group, Inc. Investment Advisor/Hedge Fund 1.8395 2364573 224672 2023-06-30 LOW
Soleus Capital Management, L.P. Hedge Fund 1.6336 2100000 2100000 2023-06-30 HIGH
Baker Bros. Advisors LP Hedge Fund 1.4624 1879915 0 2023-06-30 LOW
CIBC Asset Management Inc. Investment Advisor 1.4204 1825910 295425 2023-09-30 LOW
Acadian Asset Management LLC Investment Advisor/Hedge Fund 1.2005 1543217 146810 2023-06-30 MED

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
Leverage
1:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

Praxis Precision Medicines, Inc. Company profile

About Praxis Precision Medicines Inc

Praxis Precision Medicines, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal imbalance. Its development stage products include PRAX-114, PRAX-944 and PRAX-562. PRAX-114 is an extrasynaptic-preferring gamma-aminobutyric acid-A (GABAA) receptor positive allosteric modulator (PAM) for the treatment of patients suffering from major depressive disorder (MDD) and perimenopausal depression (PMD). PRAX-944 is a differentiated selective small molecule inhibitor of T-type calcium channel, for the treatment of essential tremor (ET). PRAX-562 is the selective, persistent sodium current blocker in development for the treatment of a range of CNS disorders.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, Praxis Precision Medicines Inc revenues was not reported. Net loss applicable to common stockholders increased from $70.3M to $167.1M. Higher net loss reflects Stock based compensation increase from $43.6M to $89.2M (expense), General and administrative increase from $13.1M to $33.7M (expense), Stock-based Compensation in SGA increase from $3.9M to $13.3M (expense).

Industry: Biotechnology & Medical Research (NEC)

99 High Street, 30th Floor
BOSTON
MASSACHUSETTS 02110
US

Income Statement

  • Annual
  • Quarterly

News

CPI drops more than expected in Europe, Spain’s IBEX 35 looking to break pre-COVID highs

CPI drops more than expected in Europe, Spain’s IBEX 35 looking to break pre-COVID highs

12:39, 30 November 2023

Euro Zone CPI expected to continue dropping; economists warn about cutting too soon

EZ PI expected to drop further but speed of decline

08:16, 29 November 2023

A weaker Dollar drives gold higher

Gold prices have returned above $US2000 per ounce. We run through the factors driving gold and the commodity’s key technicals.

13:49, 28 November 2023

Q3 US Earnings Recap: Profits surprise to the upside, but outlook remains uncertain

US earnings for the third quarter were far better than expected. However, uncertainty about the outlook for company profits continues. We review the quarterly earnings and look ahead to what the markets expect from S&P 500 companies going forward.

13:20, 28 November 2023

RBNZ Preview: Rates expected to remain unchanged at final meeting of 2023

The RBNZ meets for the final time this year on Wednesday, 29th of November, 2023. We preview what to expect and how it could impact the New Zealand Dollar.

13:04, 28 November 2023

Crude prices slide on OPEC+ uncertainty

Crude prices have chopped sideways amid signs of turmoil within OPEC+. We look at the fundamentals of the oil market and the technical levels of WTI.

12:55, 28 November 2023
GBP

UK AUTUMN BUDGET: Will Hunt cut taxes? How will GBP react this time around?

UK Chancellor Hunt will deliver the 2023 autumn statement to MPs on Wednesday 22 November.

10:48, 21 November 2023

People also watch

BTC/USD

38,882.05 Price
+0.080% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 22:00 (UTC)
Spread 106.00

Gold

2,072.25 Price
+1.760% 1D Chg, %
Long position overnight fee -0.0193%
Short position overnight fee 0.0111%
Overnight fee time 22:00 (UTC)
Spread 0.30

US100

16,001.20 Price
+0.470% 1D Chg, %
Long position overnight fee -0.0262%
Short position overnight fee 0.0040%
Overnight fee time 22:00 (UTC)
Spread 7.0

Oil - Crude

74.50 Price
-1.560% 1D Chg, %
Long position overnight fee -0.0136%
Short position overnight fee -0.0083%
Overnight fee time 22:00 (UTC)
Spread 0.040

Still looking for a broker you can trust?

Join the 570.000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading